Skip to main content

Table 1 Demographic and baseline characteristics—First-In-Human

From: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Number of subjects

AAB-003

 

0.5 mg/kg (N = 6)

1 mg/kg (N = 6)

2 mg/kg (N = 16)

4 mg/kg (N = 17)

8 mg/kg (N = 24)

Placebo (N = 19)

Age (years), mean (SD)

64.5 (6.4)

67.2 (7.4)

70.7 (10.8)

71.5 (8.8)

64.5 (7.6)

71.1 (7.6)

Sex, n

      

 Male

2

3

2

8

10

12

 Female

4

3

14

9

14

7

Ethnicity, n

      

 White

4

3

5

6

12

11

 Black

2

2

1

0

1

3

 Asian

0

1

10

11

11

5

Weight (kg) mean (SD)

70.9 (13.4)

69.8 (18.4)

58.0 (10.7)

64.1 (10.5)

70.8 (17.5)

74.1 (21.8)

MMSE score, mean (SD)

22.7 (1.37)

22.5 (2.43)

20.8 (3.71)

20.1 (3.00)

21.2 (2.82)

21.2 (3.78)

  1. MMSE Mini-Mental State Exam, SD Standard deviation